Home Jurisdiction Bexion Pharmaceuticals, Inc. Welcomes New Chief Financial Officer

Bexion Pharmaceuticals, Inc. Welcomes New Chief Financial Officer

0

Ms. LaViscount brings more than 30 years of experience in start-ups to Fortune 100 companies with various leadership roles in finance, accounting and operations. Prior to joining Bexion Pharmaceuticals, Joyce served as Chief Financial Officer for Panavance Therapeutics, a clinical-stage pharmaceutical company focusing on novel oncology treatment. Prior to Panavance, Ms. LaViscount served as Chief Financial Officer and Chief Operating Officer for Helius Medical Technologies, raising over USD 110m to finance the development of the company and to secure the quotations on the Nasdaq and Toronto Exchanges. His industry foundation is based on more than 20 years of roles of increasing responsibility at Pfizer/Pharmacia, Bristol-Myers Squibb and Endo Pharmaceuticals.

Scott ShivelyChairman and CEO of Bexion, said, “Joyce has a proven track record of results-driven leadership, strategic thinking and financial acumen, and has a proven track record in private and public companies. We look forward to having her join our team and contribute to the continued progress of Bexion as a company as we develop our flagship BXQ-350 product and continue to strengthen our capital structure. »

I am delighted to join Bexion’s experienced leadership team at a pivotal time in the growth of the organization and look forward to leading the evolution of our capital structure and financial operating environment to continue the development of our promising pipeline,” said Joyce La Vicomte. “Bexion has stood out to me as a truly science-driven organization focused on delivering transformative therapies to patients, including our lead candidate BXQ-350, which, if approved, could change patients’ lives. with colorectal cancer and other solid tumours.

About Bexion Pharmaceuticals

Bexion Pharmaceuticals, a mid-stage clinical biopharmaceutical company, is developing a new generation of biological immunotherapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN) with potential opportunities for portfolio expansion into other cancers and broader indications of neuropathic pain. Bexion’s lead drug candidate is BXQ-350, a first-in-class biologic containing the multifunctional lysosomal activator protein, saposin C and a phosphatidylserine.

BXQ-350, an “S1P activator”, has demonstrated preclinical antitumor effects in vitro and in vivo, particularly in colorectal, brain and other solid tumors. Bexion has completed two Phase 1 monotherapy programs in adults and in a pediatric population. Phase 1 programs have demonstrated a strong safety profile with evidence of single agent activity on a range of tumors including glioblastoma multiforme (GBM), colorectal cancer and appendicular cancer. Additionally, other clinical and non-clinical data suggest that BXQ-350 has activity in chemotherapy-induced peripheral neuropathy.

Media contact: Margaret van Gilse ●859.757.1652 ● [email protected].

Forward-looking statements

THE INFORMATION CONTAINED IN THIS PRESENTATION IS CONFIDENTIAL INFORMATION. ACCORDINGLY, THE INFORMATION INCLUDED HEREIN MAY NOT BE REFERRED TO, CITED OR OTHERWISE DISCLOSED BY YOU. BY REVIEWING THIS INFORMATION, YOU ACKNOWLEDGE THE CONFIDENTIAL NATURE OF THIS INFORMATION AND AGREE TO BE BOUND BY THE TERMS OF THIS DISCLAIMER. THIS CONFIDENTIAL INFORMATION IS MADE AVAILABLE TO EACH RECIPIENT ONLY FOR HIS/HER INFORMATION AND IS SUBJECT TO CHANGE.

This document does not constitute an offer to sell or the solicitation of an offer to buy any securities. This document should not be construed as a prospectus or offering document and you should not rely on it or use it to form the final basis of any decision, contract, undertaking or any action, with respect to any proposed transaction or otherwise.

This document is private and confidential. You and your directors, officers, employees, agents and affiliates must maintain this document and any oral information provided in connection with this document in the strictest confidence and may not communicate, reproduce, distribute or disclose it to any other person, or refer to it publicly. , in whole or in part, at any time, except with our prior written consent and in accordance with research guidelines prepared in connection with this transaction. If you are not the intended recipient of this document, please delete and destroy all copies immediately.

This document has been prepared by the Company and the analyzes contained herein are based, in part, on certain assumptions made by and information obtained from the Company and/or other sources. Neither the Company nor any of their respective affiliates, officers, employees or agents make any representation or warranty, express or implied, with respect to the fairness, reasonableness, adequacy, accuracy or completeness information, statements or opinions, regardless of their source. , contained herein or any oral information provided in connection therewith, or any data it generates and accepts no liability, obligation or liability (whether direct or indirect, in contract, tort or otherwise) by related to any of this information. The information and opinions contained in this document are provided as of the date of the document, are subject to change without notice and do not purport to contain all the information that may be necessary to evaluate the Company. The information contained herein is in draft form and has not been independently verified. The Company and their respective affiliates, officers, employees and agents expressly disclaim any and all liability that may be based on this document and any errors or omissions relating thereto. Neither the Company nor any of their respective affiliates, officers, employees or agents make any representation or warranty, express or implied, that any transaction has been or may be effected on the terms or in the manner set forth herein, or as to the achievement or reasonableness of future projections, management objectives, estimates, prospects or returns, if any.

This document and any materials distributed in connection with this document are not intended for, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require registration or license in such jurisdiction. This document does not constitute an offer to sell or a solicitation of an offer to buy securities of United States or any other jurisdiction. This document may not be reproduced, redistributed, published or transmitted, directly or indirectly, to any person in any jurisdiction where it would constitute a violation of the applicable laws of that jurisdiction.

SOURCEBexion Pharmaceuticals, Inc.